Last reviewed · How we verify

NMN — Competitive Intelligence Brief

NMN (NMN) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NAD+ precursor / metabolic supplement. Area: Aging / Metabolic Health / Longevity.

marketed NAD+ precursor / metabolic supplement NAD+ biosynthesis pathway Aging / Metabolic Health / Longevity Small molecule Live · refreshed every 30 min

Target snapshot

NMN (NMN) — Shanghai Cell Therapy Group Co.,Ltd. NMN (nicotinamide mononucleotide) replenishes cellular NAD+ levels to support mitochondrial function and energy metabolism.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
NMN TARGET NMN Shanghai Cell Therapy Group Co.,Ltd marketed NAD+ precursor / metabolic supplement NAD+ biosynthesis pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NAD+ precursor / metabolic supplement class)

  1. Shanghai Cell Therapy Group Co.,Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NMN — Competitive Intelligence Brief. https://druglandscape.com/ci/nmn. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: